A 2023 retrospective cohort study found semaglutide significantly reduced binge eating episodes in patients with BED the first study of its kind A 2020 pilot study of dulaglutide found it reduced binge episodes in patients with type 2 diabetes and BED A 2026 meta-analysis found liraglutide reduced binge frequency by approximately 1.28 fewer episodes per week compared to placebo A rapid review of 25 studies encompassing over 8,700 adult patients found that binge eating episodes and prevalence reduced following liraglutide and semaglutide An observational study of 69 people with obesity found emotional eating dropped from 72.5% to 11.5% after three months of semaglutide The Critical Caveats Despite a promising early signal, these findings should be held carefully
Sentinel Valor supplies SV-PT141 as a laboratory-grade research material intended strictly for research applications and professional laboratory environments
[DOI] [PubMed] [Google Scholar] Liu P, Wang J, Wen W, Pan T, Chen H, Fu Y, Wang F, Huang JH, Xu S
For example: Semaglutide (Ozempic) is FDA-approved to reduce the risk of major adverse cardiovascular events in type 2 diabetes patients with established cardiovascular disease
Polychlorinated biphenyls, known as PCBs, are sometimes found in contaminated fish
As the body digests food, certain by-products, such as gas , are released